Today, Cytokine Release Syndrome (CRS) requires regular clinical oversight through extended hospitalizations, creating barriers to care and limiting patient access to vital immunotherapies. Digital health technologies (DHTs) have matured to a point where we can—and should—rely on them to detect the onset of CRS, enabling monitoring and risk prediction beyond the clinic.
To support, DATAcc by DiMe has developed resources to support the development of trustworthy CRS de-risking products that can enable earlier detection and management, empowering oncologists to improve patient outcomes globally.
Developers
Providers
Patients
Digital clinical measures
Innovation roadmap
The visual highlights Alexandra’s challenges and shows how a CRS de-risking product could have been used to improve her patient journey.
As immunotherapies, including those in development, become available sooner and indications expand, more patients like Alexandra will become eligible, challenging clinical staff to keep up with the growing demand for care.
Only 20% of eligible patients, like Alexandra, receive this therapy due to the complex logistics, toxicity concerns, and financial burden.
Her vitals are collected every four hours as standard of care.
Using DHTs could’ve enabled her CRS detection up to two hours earlier and supported monitoring in an outpatient setting.
Advanced CRS de-risking products could assess whether her CRS event would progress, allowing her team to manage the CRS event in the appropriate setting.
CRS de-risking products could allow Alexandra to safely distance herself from the clinic, potentially even returning home several hours away.
Partners also include the National Cancer Institute
The DiMe Seal
